Non-viral Vectors Gene Therapy Market, Global Outlook and Forecast 2022-2028

August 2022 | 69 pages | ID: N631A5123523EN
Market Monitor Global

Abstracts

Non-viral vectors for gene therapy are non-viral vehicles (particle based or chemical based) that deliver the genetic material into a wide variety of cells, tissues and whole organs to treat or improve the health condition of the patient.

This report contains market size and forecasts of Non-viral Vectors Gene Therapy in Global, including the following market information:

Global Non-viral Vectors Gene Therapy Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Non-viral Vectors Gene Therapy market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Oligonucleotides Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Non-viral Vectors Gene Therapy include Biogen, Sarepta Therapeutics, Gilead Sciences, Amgen, Novartis, Orchard Therapeutics, Spark Therapeutics, Agc Biologics and Anges, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Non-viral Vectors Gene Therapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Non-viral Vectors Gene Therapy Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Non-viral Vectors Gene Therapy Market Segment Percentages, by Type, 2021 (%)

• Oligonucleotides
• Other Non-viral Vectors

Global Non-viral Vectors Gene Therapy Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Non-viral Vectors Gene Therapy Market Segment Percentages, by Application, 2021 (%)

• In Vivo
• Ex Vivo

Global Non-viral Vectors Gene Therapy Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Non-viral Vectors Gene Therapy Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Non-viral Vectors Gene Therapy revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Non-viral Vectors Gene Therapy revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Biogen
• Sarepta Therapeutics
• Gilead Sciences
• Amgen
• Novartis
• Orchard Therapeutics
• Spark Therapeutics
• Agc Biologics
• Anges
• Bluebird Bio
• Jazz Pharmaceuticals
• Dynavax Technologies

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Non-viral Vectors Gene Therapy Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Non-viral Vectors Gene Therapy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL NON-VIRAL VECTORS GENE THERAPY OVERALL MARKET SIZE

2.1 Global Non-viral Vectors Gene Therapy Market Size: 2021 VS 2028
2.2 Global Non-viral Vectors Gene Therapy Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Non-viral Vectors Gene Therapy Players in Global Market
3.2 Top Global Non-viral Vectors Gene Therapy Companies Ranked by Revenue
3.3 Global Non-viral Vectors Gene Therapy Revenue by Companies
3.4 Top 3 and Top 5 Non-viral Vectors Gene Therapy Companies in Global Market, by Revenue in 2021
3.5 Global Companies Non-viral Vectors Gene Therapy Product Type
3.6 Tier 1, Tier 2 and Tier 3 Non-viral Vectors Gene Therapy Players in Global Market
  3.6.1 List of Global Tier 1 Non-viral Vectors Gene Therapy Companies
  3.6.2 List of Global Tier 2 and Tier 3 Non-viral Vectors Gene Therapy Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Non-viral Vectors Gene Therapy Market Size Markets, 2021 & 2028
  4.1.2 Oligonucleotides
  4.1.3 Other Non-viral Vectors
4.2 By Type - Global Non-viral Vectors Gene Therapy Revenue & Forecasts
  4.2.1 By Type - Global Non-viral Vectors Gene Therapy Revenue, 2017-2022
  4.2.2 By Type - Global Non-viral Vectors Gene Therapy Revenue, 2023-2028
  4.2.3 By Type - Global Non-viral Vectors Gene Therapy Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Non-viral Vectors Gene Therapy Market Size, 2021 & 2028
  5.1.2 In Vivo
  5.1.3 Ex Vivo
5.2 By Application - Global Non-viral Vectors Gene Therapy Revenue & Forecasts
  5.2.1 By Application - Global Non-viral Vectors Gene Therapy Revenue, 2017-2022
  5.2.2 By Application - Global Non-viral Vectors Gene Therapy Revenue, 2023-2028
  5.2.3 By Application - Global Non-viral Vectors Gene Therapy Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Non-viral Vectors Gene Therapy Market Size, 2021 & 2028
6.2 By Region - Global Non-viral Vectors Gene Therapy Revenue & Forecasts
  6.2.1 By Region - Global Non-viral Vectors Gene Therapy Revenue, 2017-2022
  6.2.2 By Region - Global Non-viral Vectors Gene Therapy Revenue, 2023-2028
  6.2.3 By Region - Global Non-viral Vectors Gene Therapy Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Non-viral Vectors Gene Therapy Revenue, 2017-2028
  6.3.2 US Non-viral Vectors Gene Therapy Market Size, 2017-2028
  6.3.3 Canada Non-viral Vectors Gene Therapy Market Size, 2017-2028
  6.3.4 Mexico Non-viral Vectors Gene Therapy Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Non-viral Vectors Gene Therapy Revenue, 2017-2028
  6.4.2 Germany Non-viral Vectors Gene Therapy Market Size, 2017-2028
  6.4.3 France Non-viral Vectors Gene Therapy Market Size, 2017-2028
  6.4.4 U.K. Non-viral Vectors Gene Therapy Market Size, 2017-2028
  6.4.5 Italy Non-viral Vectors Gene Therapy Market Size, 2017-2028
  6.4.6 Russia Non-viral Vectors Gene Therapy Market Size, 2017-2028
  6.4.7 Nordic Countries Non-viral Vectors Gene Therapy Market Size, 2017-2028
  6.4.8 Benelux Non-viral Vectors Gene Therapy Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Non-viral Vectors Gene Therapy Revenue, 2017-2028
  6.5.2 China Non-viral Vectors Gene Therapy Market Size, 2017-2028
  6.5.3 Japan Non-viral Vectors Gene Therapy Market Size, 2017-2028
  6.5.4 South Korea Non-viral Vectors Gene Therapy Market Size, 2017-2028
  6.5.5 Southeast Asia Non-viral Vectors Gene Therapy Market Size, 2017-2028
  6.5.6 India Non-viral Vectors Gene Therapy Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Non-viral Vectors Gene Therapy Revenue, 2017-2028
  6.6.2 Brazil Non-viral Vectors Gene Therapy Market Size, 2017-2028
  6.6.3 Argentina Non-viral Vectors Gene Therapy Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Non-viral Vectors Gene Therapy Revenue, 2017-2028
  6.7.2 Turkey Non-viral Vectors Gene Therapy Market Size, 2017-2028
  6.7.3 Israel Non-viral Vectors Gene Therapy Market Size, 2017-2028
  6.7.4 Saudi Arabia Non-viral Vectors Gene Therapy Market Size, 2017-2028
  6.7.5 UAE Non-viral Vectors Gene Therapy Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Biogen
  7.1.1 Biogen Corporate Summary
  7.1.2 Biogen Business Overview
  7.1.3 Biogen Non-viral Vectors Gene Therapy Major Product Offerings
  7.1.4 Biogen Non-viral Vectors Gene Therapy Revenue in Global Market (2017-2022)
  7.1.5 Biogen Key News
7.2 Sarepta Therapeutics
  7.2.1 Sarepta Therapeutics Corporate Summary
  7.2.2 Sarepta Therapeutics Business Overview
  7.2.3 Sarepta Therapeutics Non-viral Vectors Gene Therapy Major Product Offerings
  7.2.4 Sarepta Therapeutics Non-viral Vectors Gene Therapy Revenue in Global Market (2017-2022)
  7.2.5 Sarepta Therapeutics Key News
7.3 Gilead Sciences
  7.3.1 Gilead Sciences Corporate Summary
  7.3.2 Gilead Sciences Business Overview
  7.3.3 Gilead Sciences Non-viral Vectors Gene Therapy Major Product Offerings
  7.3.4 Gilead Sciences Non-viral Vectors Gene Therapy Revenue in Global Market (2017-2022)
  7.3.5 Gilead Sciences Key News
7.4 Amgen
  7.4.1 Amgen Corporate Summary
  7.4.2 Amgen Business Overview
  7.4.3 Amgen Non-viral Vectors Gene Therapy Major Product Offerings
  7.4.4 Amgen Non-viral Vectors Gene Therapy Revenue in Global Market (2017-2022)
  7.4.5 Amgen Key News
7.5 Novartis
  7.5.1 Novartis Corporate Summary
  7.5.2 Novartis Business Overview
  7.5.3 Novartis Non-viral Vectors Gene Therapy Major Product Offerings
  7.5.4 Novartis Non-viral Vectors Gene Therapy Revenue in Global Market (2017-2022)
  7.5.5 Novartis Key News
7.6 Orchard Therapeutics
  7.6.1 Orchard Therapeutics Corporate Summary
  7.6.2 Orchard Therapeutics Business Overview
  7.6.3 Orchard Therapeutics Non-viral Vectors Gene Therapy Major Product Offerings
  7.6.4 Orchard Therapeutics Non-viral Vectors Gene Therapy Revenue in Global Market (2017-2022)
  7.6.5 Orchard Therapeutics Key News
7.7 Spark Therapeutics
  7.7.1 Spark Therapeutics Corporate Summary
  7.7.2 Spark Therapeutics Business Overview
  7.7.3 Spark Therapeutics Non-viral Vectors Gene Therapy Major Product Offerings
  7.7.4 Spark Therapeutics Non-viral Vectors Gene Therapy Revenue in Global Market (2017-2022)
  7.7.5 Spark Therapeutics Key News
7.8 Agc Biologics
  7.8.1 Agc Biologics Corporate Summary
  7.8.2 Agc Biologics Business Overview
  7.8.3 Agc Biologics Non-viral Vectors Gene Therapy Major Product Offerings
  7.8.4 Agc Biologics Non-viral Vectors Gene Therapy Revenue in Global Market (2017-2022)
  7.8.5 Agc Biologics Key News
7.9 Anges
  7.9.1 Anges Corporate Summary
  7.9.2 Anges Business Overview
  7.9.3 Anges Non-viral Vectors Gene Therapy Major Product Offerings
  7.9.4 Anges Non-viral Vectors Gene Therapy Revenue in Global Market (2017-2022)
  7.9.5 Anges Key News
7.10 Bluebird Bio
  7.10.1 Bluebird Bio Corporate Summary
  7.10.2 Bluebird Bio Business Overview
  7.10.3 Bluebird Bio Non-viral Vectors Gene Therapy Major Product Offerings
  7.10.4 Bluebird Bio Non-viral Vectors Gene Therapy Revenue in Global Market (2017-2022)
  7.10.5 Bluebird Bio Key News
7.11 Jazz Pharmaceuticals
  7.11.1 Jazz Pharmaceuticals Corporate Summary
  7.11.2 Jazz Pharmaceuticals Business Overview
  7.11.3 Jazz Pharmaceuticals Non-viral Vectors Gene Therapy Major Product Offerings
  7.11.4 Jazz Pharmaceuticals Non-viral Vectors Gene Therapy Revenue in Global Market (2017-2022)
  7.11.5 Jazz Pharmaceuticals Key News
7.12 Dynavax Technologies
  7.12.1 Dynavax Technologies Corporate Summary
  7.12.2 Dynavax Technologies Business Overview
  7.12.3 Dynavax Technologies Non-viral Vectors Gene Therapy Major Product Offerings
  7.12.4 Dynavax Technologies Non-viral Vectors Gene Therapy Revenue in Global Market (2017-2022)
  7.12.5 Dynavax Technologies Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Non-viral Vectors Gene Therapy Market Opportunities & Trends in Global Market
Table 2. Non-viral Vectors Gene Therapy Market Drivers in Global Market
Table 3. Non-viral Vectors Gene Therapy Market Restraints in Global Market
Table 4. Key Players of Non-viral Vectors Gene Therapy in Global Market
Table 5. Top Non-viral Vectors Gene Therapy Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Non-viral Vectors Gene Therapy Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Non-viral Vectors Gene Therapy Revenue Share by Companies, 2017-2022
Table 8. Global Companies Non-viral Vectors Gene Therapy Product Type
Table 9. List of Global Tier 1 Non-viral Vectors Gene Therapy Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Non-viral Vectors Gene Therapy Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Non-viral Vectors Gene Therapy Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Non-viral Vectors Gene Therapy Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Non-viral Vectors Gene Therapy Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Non-viral Vectors Gene Therapy Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Non-viral Vectors Gene Therapy Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Non-viral Vectors Gene Therapy Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2023-2028
Table 30. Biogen Corporate Summary
Table 31. Biogen Non-viral Vectors Gene Therapy Product Offerings
Table 32. Biogen Non-viral Vectors Gene Therapy Revenue (US$, Mn), (2017-2022)
Table 33. Sarepta Therapeutics Corporate Summary
Table 34. Sarepta Therapeutics Non-viral Vectors Gene Therapy Product Offerings
Table 35. Sarepta Therapeutics Non-viral Vectors Gene Therapy Revenue (US$, Mn), (2017-2022)
Table 36. Gilead Sciences Corporate Summary
Table 37. Gilead Sciences Non-viral Vectors Gene Therapy Product Offerings
Table 38. Gilead Sciences Non-viral Vectors Gene Therapy Revenue (US$, Mn), (2017-2022)
Table 39. Amgen Corporate Summary
Table 40. Amgen Non-viral Vectors Gene Therapy Product Offerings
Table 41. Amgen Non-viral Vectors Gene Therapy Revenue (US$, Mn), (2017-2022)
Table 42. Novartis Corporate Summary
Table 43. Novartis Non-viral Vectors Gene Therapy Product Offerings
Table 44. Novartis Non-viral Vectors Gene Therapy Revenue (US$, Mn), (2017-2022)
Table 45. Orchard Therapeutics Corporate Summary
Table 46. Orchard Therapeutics Non-viral Vectors Gene Therapy Product Offerings
Table 47. Orchard Therapeutics Non-viral Vectors Gene Therapy Revenue (US$, Mn), (2017-2022)
Table 48. Spark Therapeutics Corporate Summary
Table 49. Spark Therapeutics Non-viral Vectors Gene Therapy Product Offerings
Table 50. Spark Therapeutics Non-viral Vectors Gene Therapy Revenue (US$, Mn), (2017-2022)
Table 51. Agc Biologics Corporate Summary
Table 52. Agc Biologics Non-viral Vectors Gene Therapy Product Offerings
Table 53. Agc Biologics Non-viral Vectors Gene Therapy Revenue (US$, Mn), (2017-2022)
Table 54. Anges Corporate Summary
Table 55. Anges Non-viral Vectors Gene Therapy Product Offerings
Table 56. Anges Non-viral Vectors Gene Therapy Revenue (US$, Mn), (2017-2022)
Table 57. Bluebird Bio Corporate Summary
Table 58. Bluebird Bio Non-viral Vectors Gene Therapy Product Offerings
Table 59. Bluebird Bio Non-viral Vectors Gene Therapy Revenue (US$, Mn), (2017-2022)
Table 60. Jazz Pharmaceuticals Corporate Summary
Table 61. Jazz Pharmaceuticals Non-viral Vectors Gene Therapy Product Offerings
Table 62. Jazz Pharmaceuticals Non-viral Vectors Gene Therapy Revenue (US$, Mn), (2017-2022)
Table 63. Dynavax Technologies Corporate Summary
Table 64. Dynavax Technologies Non-viral Vectors Gene Therapy Product Offerings
Table 65. Dynavax Technologies Non-viral Vectors Gene Therapy Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Non-viral Vectors Gene Therapy Segment by Type in 2021
Figure 2. Non-viral Vectors Gene Therapy Segment by Application in 2021
Figure 3. Global Non-viral Vectors Gene Therapy Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Non-viral Vectors Gene Therapy Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Non-viral Vectors Gene Therapy Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Non-viral Vectors Gene Therapy Revenue in 2021
Figure 8. By Type - Global Non-viral Vectors Gene Therapy Revenue Market Share, 2017-2028
Figure 9. By Application - Global Non-viral Vectors Gene Therapy Revenue Market Share, 2017-2028
Figure 10. By Region - Global Non-viral Vectors Gene Therapy Revenue Market Share, 2017-2028
Figure 11. By Country - North America Non-viral Vectors Gene Therapy Revenue Market Share, 2017-2028
Figure 12. US Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Non-viral Vectors Gene Therapy Revenue Market Share, 2017-2028
Figure 16. Germany Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2017-2028
Figure 17. France Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Non-viral Vectors Gene Therapy Revenue Market Share, 2017-2028
Figure 24. China Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2017-2028
Figure 28. India Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Non-viral Vectors Gene Therapy Revenue Market Share, 2017-2028
Figure 30. Brazil Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Non-viral Vectors Gene Therapy Revenue Market Share, 2017-2028
Figure 33. Turkey Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Non-viral Vectors Gene Therapy Revenue, (US$, Mn), 2017-2028
Figure 37. Biogen Non-viral Vectors Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Sarepta Therapeutics Non-viral Vectors Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Gilead Sciences Non-viral Vectors Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Amgen Non-viral Vectors Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Novartis Non-viral Vectors Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Orchard Therapeutics Non-viral Vectors Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Spark Therapeutics Non-viral Vectors Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Agc Biologics Non-viral Vectors Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Anges Non-viral Vectors Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Bluebird Bio Non-viral Vectors Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Jazz Pharmaceuticals Non-viral Vectors Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Dynavax Technologies Non-viral Vectors Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)